Research map: Collaborating for Affordable Patient Access to Medicines: Review of the First Decade of the Beneluxa Initiative in Pharmaceutical Policy

Back to the article

Papers in this map

  1. European collaborations on medicine and vaccine procurement · Sabine Vogler · 2021 · 229 citations · Cited by this paper
  2. Costs and Budget Impact of a Health System Strengthening Intervention for Hypertension and Cardiovascular Disease Care in Ghana · 2026 · Related
  3. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries · Sabine Vogler · 2017 · 204 citations · Cited by this paper
  4. Active Transport Health Model: Valuing the Health Benefits of Active Transport · 2026 · Related
  5. Pricing of pharmaceuticals is becoming a major challenge for health systems · Steven G. Morgan · 2020 · 145 citations · Cited by this paper
  6. Integrating Equity in Topic Selection for Orphan Medicinal Products: Policy Implications for Health Technology Assessment in Rare Diseases · 2026 · Related
  7. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries · Gabriel Seidman · 2017 · 136 citations · Cited by this paper
  8. Funding Health Promotion Activities to Reduce Avoidable Hospital Admissions in Frail Older Adults (HomeHealth): Further Challenges to the “Cost-Effective but Unaffordable” Paradox · 2025 · Related
  9. Generating comparative evidence on new drugs and devices before approval · Huseyin Naci · 2020 · 82 citations · Cited by this paper
  10. Action Plan to Better Approximate Reality in Cost-Effectiveness Analyses · 2026 · Related
  11. Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers · Josh John Carlson · 2014 · 66 citations · Cited by this paper
  12. The Price of Speed: Estimating the Impact of List Prices on Time to Availability of New Medicines in 18 European Countries · 2026 · Related
  13. High drug prices are not justified by industry’s spending on research and development · Aris Angelis · 2023 · 52 citations · Cited by this paper
  14. Agreement in Qualitative and Quantitative Assessments of Disease Severity: Evidence from Pharmaceutical Reimbursement in Sweden · 2026 · Related
  15. Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America · Daniela Moye-Holz · 2021 · 48 citations · Cited by this paper
  16. Which Factors are Holding up the Integration of the Environmental Impact of Health Technologies in Health Technology Assessment? Insights from a Multi-Stakeholder Interview Study · 2025 · Related
  17. Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study · Francine Brinkhuis · 2024 · 42 citations · Cited by this paper
  18. Negotiating prices of drugs for rare diseases · Séverine Henrard · 2016 · 41 citations · Cited by this paper
  19. Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review · Dominik J. Wettstein · 2018 · 30 citations · Cited by this paper
  20. Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline? · C.T. Leonard · 2023 · 29 citations · Cited by this paper
  21. Centralised Pharmaceutical Procurement: Learnings from Six European Countries · Sabine Vogler · 2022 · 28 citations · Cited by this paper
  22. Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference · Sabine Vogler · 2016 · 23 citations · Cited by this paper
  23. Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape · Evert A. Manders · 2024 · 22 citations · Cited by this paper
  24. Strategic procurement and international collaboration to improve access to medicines · Alessandra Ferrario · 2017 · 20 citations · Cited by this paper
  25. Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries · Sabine Vogler · 2019 · 19 citations · Cited by this paper
  26. What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France · Marion Tano · 2023 · 17 citations · Cited by this paper
  27. Preferences on Policy Options for Ensuring the Financial Sustainability of Health Care Services in the Future: Results of a Stakeholder Survey · David Tordrup · 2013 · 13 citations · Cited by this paper
  28. Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System · Irene Eriksson · 2018 · 13 citations · Cited by this paper
  29. Accelerating access to medicines in a changing world · Hannah E. Kettler · 2020 · 9 citations · Cited by this paper
  30. Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing · Zoltán Kaló · 2025 · 9 citations · Cited by this paper
  31. Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally · Sabine Vogler · 2024 · 7 citations · Cited by this paper
  32. Alternative Payment Models for Innovative Medicines: A Framework for Effective Implementation · Frederick McElwee · 2025 · 6 citations · Cited by this paper
  33. Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe · Christopher Henshall · 2023 · 5 citations · Cited by this paper
  34. Systematic Literature Review of Access Pathways to Drugs for Patients with Rare Diseases · Constanza Vargas · 2024 · 5 citations · Cited by this paper
  35. Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements · Tarang Sharma · 2025 · 5 citations · Cited by this paper
  36. The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries’ past health technology assessments · Rick A. Vreman · 2023 · 4 citations · Cited by this paper
  37. Horizon scanning for pharmaceuticals · Isabelle Lepage-Nefkens · 2017 · 3 citations · Cited by this paper
  38. How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU · Róisín Louise Adams · 2026 · 3 citations · Cited by this paper
  39. Mechanisms Considering Public Investment in Pricing and Reimbursement Decisions of Medicines and Other Health Technologies: A Scoping Review · Mario García-Díaz · 2025 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)